Found: 1381
Select item for more details and to access through your institution.
Doxycycline Plus Bortezomib-Containing Regimens for the Treatment of Light-Chain Amyloidosis in the Frontline Setting: Experience from the Amyloidosis Program of Calgary.
- Published in:
- Current Oncology, 2024, v. 31, n. 9, p. 5608, doi. 10.3390/curroncol31090415
- By:
- Publication type:
- Article
Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma.
- Published in:
- BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12880-9
- By:
- Publication type:
- Article
Optimizing Outcomes in the Management of Multiple Myeloma: Key Managed Care Considerations on the Evolving Role of Anti-CD38 Therapy.
- Published in:
- Journal of Managed Care Medicine, 2024, v. 27, n. 2, p. 44
- By:
- Publication type:
- Article
Travmaya Bağlı Fraktür Gelişimi Sonucu Multipl Miyelom Tanısı Alan Hastanın Hemşirelik Bakımı: Olgu Sunumu.
- Published in:
- Journal of Ege University Nursing Faculty (JEUNF), 2024, v. 40, n. 2, p. 293, doi. 10.53490/egehemsire.1153032
- By:
- Publication type:
- Article
Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 5, p. 651, doi. 10.1007/s41669-024-00503-9
- By:
- Publication type:
- Article
Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients.
- Published in:
- Wiener Klinische Wochenschrift, 2017, v. 129, n. 15/16, p. 545, doi. 10.1007/s00508-017-1205-z
- By:
- Publication type:
- Article
Ki-67 proliferation index in patients with placenta previa percreta in the third trimester.
- Published in:
- Wiener Klinische Wochenschrift, 2015, v. 127, n. 3/4, p. 98, doi. 10.1007/s00508-014-0634-1
- By:
- Publication type:
- Article
Histiocytoid sweet syndrome related to bortezomib: A mimicker of cutaneous infiltration by myeloma.
- Published in:
- Indian Journal of Dermatology, Venereology & Leprology, 2015, v. 81, n. 3, p. 305, doi. 10.4103/0378-6323.152743
- By:
- Publication type:
- Article
Drug-Induced Modulation of T Lymphocytes as a Potential Mechanism of Susceptibility to Infections in Patients with Multiple Myeloma During Bortezomib Therapy.
- Published in:
- Cell Biochemistry & Biophysics, 2015, v. 71, n. 1, p. 457, doi. 10.1007/s12013-014-0224-x
- By:
- Publication type:
- Article
Effect of proteasome inhibitors on canine lymphoma cell response to CHOP chemotherapy in vitro.
- Published in:
- Veterinary & Comparative Oncology, 2024, v. 22, n. 1, p. 96, doi. 10.1111/vco.12957
- By:
- Publication type:
- Article
A Review of The Synergistic Effects of Curcumin with Proteasome Inhibitors in Multiple Myeloma Preclinical Models.
- Published in:
- Integrative Cancer Therapies, 2023, v. 22, p. 1, doi. 10.1177/15347354231159322
- By:
- Publication type:
- Article
Prevention of Bortezomib-Induced Peripheral Neuropathy in Newly Multiple Myeloma Patients Using Nervonic Acid, Curcuma Rizoma, and L-Arginine Compound: A Pilot Study.
- Published in:
- Integrative Cancer Therapies, 2022, v. 21, p. 1, doi. 10.1177/15347354221114142
- By:
- Publication type:
- Article
The Effect of Docosahexaenoic Acid and α-Lipoic Acid as Prevention of Bortezomib-Related Neurotoxicity in Patients With Multiple Myeloma.
- Published in:
- Integrative Cancer Therapies, 2019, v. 18, p. 1, doi. 10.1177/1534735419888584
- By:
- Publication type:
- Article
Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data.
- Published in:
- Integrative Cancer Therapies, 2018, v. 17, n. 4, p. 1115, doi. 10.1177/1534735418803758
- By:
- Publication type:
- Article
Acupuncture for Bortezomib-Induced Peripheral Neuropathy: Not Just for Pain.
- Published in:
- Integrative Cancer Therapies, 2018, v. 17, n. 4, p. 1079, doi. 10.1177/1534735418788667
- By:
- Publication type:
- Article
A Pilot Study of Acupuncture in Treating Bortezomib-Induced Peripheral Neuropathy in Patients With Multiple Myeloma.
- Published in:
- Integrative Cancer Therapies, 2014, v. 13, n. 5, p. 396, doi. 10.1177/1534735414534729
- By:
- Publication type:
- Article
Impact of dose modification on intravenous Bortezomib-induced peripheral neuropathy in multiple myeloma patients.
- Published in:
- Supportive Care in Cancer, 2014, v. 22, n. 10, p. 2669, doi. 10.1007/s00520-014-2256-6
- By:
- Publication type:
- Article
Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Oral manifestations of amyloidosis in a multiple myeloma patient: A case report.
- Published in:
- Acta Marisiensis. Seria Medica, 2023, v. 69, n. 2, p. 131, doi. 10.2478/amma-2023-0019
- By:
- Publication type:
- Article
The Treatment-induced Neuropathy Assessment Scale (TNAS): a psychometric update following qualitative enrichment.
- Published in:
- Journal of Patient-Reported Outcomes, 2020, v. 4, n. 1, p. 1, doi. 10.1186/s41687-020-0180-8
- By:
- Publication type:
- Article
EFFECT OF NORDIC WALKING TRAINING COMBINED WITH INTERMITTENT FASTING ON SERUM LEVELS OF WNT PATHWAY INHIBITORS IN PATIENTS WITH PLASMOCYTIC MYELOMA.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
Bortezomib exerts its anti-cancer activity through the regulation of Skp2/p53 axis in non-melanoma skin cancer cells and C. elegans.
- Published in:
- Cell Death Discovery, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41420-024-01992-7
- By:
- Publication type:
- Article
Report of a fulminant anti‐pan‐neurofascin‐associated neuropathy responsive to rituximab and bortezomib.
- Published in:
- Journal of the Peripheral Nervous System, 2021, v. 26, n. 4, p. 475, doi. 10.1111/jns.12465
- By:
- Publication type:
- Article
Bortezomib and other proteosome inhibitors—induced peripheral neurotoxicity: From pathogenesis to treatment.
- Published in:
- Journal of the Peripheral Nervous System, 2019, v. 24, n. 2, p. S52, doi. 10.1111/jns.12338
- By:
- Publication type:
- Article
多发性骨髓瘤患者硼替佐米治疗相关带状疱疹发病机理 及预防策略研究进展
- Published in:
- Progress in Modern Biomedicine, 2019, v. 19, n. 13, p. 2592, doi. 10.13241/j.cnki.pmb.2019.13.044
- By:
- Publication type:
- Article
Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.
- Published in:
- Oncology Research & Treatment, 2020, v. 43, n. 9, p. 449, doi. 10.1159/000509018
- By:
- Publication type:
- Article
Plasma cell leukaemia: a management conundrum.
- Published in:
- 2014
- By:
- Publication type:
- Case Study
Practical considerations for the integration of subcutaneous targeted therapies into the oncology clinic.
- Published in:
- Canadian Oncology Nursing Journal, 2019, v. 29, n. 4, p. 267
- By:
- Publication type:
- Article
Azithromycin inhibits nuclear factor- κB activation during lung inflammation: an in vivo imaging study.
- Published in:
- Pharmacology Research & Perspectives, 2014, v. 2, n. 5, p. n/a, doi. 10.1002/prp2.58
- By:
- Publication type:
- Article
Inhibition of Proteasome Activity by Low-dose Bortezomib Attenuates Angiotensin II-induced Abdominal Aortic Aneurysm in Apo E<sup>−/−</sup> Mice.
- Published in:
- Scientific Reports, 2015, p. 15730, doi. 10.1038/srep15730
- By:
- Publication type:
- Article
Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth.
- Published in:
- Scientific Reports, 2015, p. 8428, doi. 10.1038/ncomms9428
- By:
- Publication type:
- Article
Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl/6 mice.
- Published in:
- Scientific Reports, 2014, p. 1, doi. 10.1038/srep06370
- By:
- Publication type:
- Article
A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.
- Published in:
- Scientific Reports, 2014, p. 1, doi. 10.1038/srep05240
- By:
- Publication type:
- Article
Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation.
- Published in:
- Cells (2073-4409), 2023, v. 12, n. 6, p. 960, doi. 10.3390/cells12060960
- By:
- Publication type:
- Article
The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma.
- Published in:
- Cells (2073-4409), 2021, v. 10, n. 12, p. 3464, doi. 10.3390/cells10123464
- By:
- Publication type:
- Article
High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors.
- Published in:
- Cells (2073-4409), 2021, v. 10, n. 11, p. 2853, doi. 10.3390/cells10112853
- By:
- Publication type:
- Article
Caspase-Dependent HMGB1 Release from Macrophages Participates in Peripheral Neuropathy Caused by Bortezomib, a Proteasome-Inhibiting Chemotherapeutic Agent, in Mice.
- Published in:
- Cells (2073-4409), 2021, v. 10, n. 10, p. 2550, doi. 10.3390/cells10102550
- By:
- Publication type:
- Article
Omega-3 Fatty Acids DHA and EPA Reduce Bortezomib Resistance in Multiple Myeloma Cells by Promoting Glutathione Degradation.
- Published in:
- 2021
- By:
- Publication type:
- Abstract
Large-Scale Drug Screening in Patient-Derived IDHmut Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents.
- Published in:
- Cells (2073-4409), 2020, v. 9, n. 6, p. 1389, doi. 10.3390/cells9061389
- By:
- Publication type:
- Article
Quadruplet regimen for newly diagnosed multiple myeloma is effective in the standard-risk subgroup but not in the high-risk subgroup.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1398879
- By:
- Publication type:
- Article
Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1351565
- By:
- Publication type:
- Article
SARS-CoV-2 Nsp14 protein associates with IMPDH2 and activates NF-κB signaling.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.1007089
- By:
- Publication type:
- Article
Road testing new CAR design strategies in multiple myeloma.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.957157
- By:
- Publication type:
- Article
Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.838406
- By:
- Publication type:
- Article
Primary Plurifocal Extramedullary Plasmacytoma of Breast.
- Published in:
- Breast Journal, 2016, v. 22, n. 4, p. 465, doi. 10.1111/tbj.12601
- By:
- Publication type:
- Article
Monoclonal gammopathy of renal significance triggering atypical haemolytic uraemic syndrome.
- Published in:
- Nephrology, 2017, v. 22, p. 15, doi. 10.1111/nep.12934
- By:
- Publication type:
- Article
Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
- Published in:
- Nephrology, 2016, v. 21, n. 8, p. 700, doi. 10.1111/nep.12659
- By:
- Publication type:
- Article
Treatment of acute antibody-mediated rejection using bortezomib: a case report.
- Published in:
- Nephrology, 2015, v. 20, p. 86, doi. 10.1111/nep.12459
- By:
- Publication type:
- Article
Bortezomib in ABO-incompatible kidney transplant desensitization: A case report.
- Published in:
- Nephrology, 2015, v. 20, p. 22, doi. 10.1111/nep.12424
- By:
- Publication type:
- Article
Aggressive immunotherapy combined with bortezomib and rituximab for membranous nephropathy associated with enzyme replacement therapy in Pompe disease.
- Published in:
- Pediatric Nephrology, 2023, v. 38, n. 3, p. 921, doi. 10.1007/s00467-022-05672-5
- By:
- Publication type:
- Article